Clinical Trial

Artificial Intelligence in Assessing Gastric Intestinal Metaplasia Via the EGGIM Score

Recruiting
View on ClinicalTrials.gov →
Summary
The endoscopic grading system (EGGIM) has been widely used to assess the extent of gastric intestinal metaplasia during endoscopy. Investigators developed an artificial intelligence (AI) system to automatically evaluate the extent of gastric intestinal metaplasia (GIM) and calculate the EGGIM scores in endoscopy examination. This study is a prospective, multi-center study aimed at exploring the performance and reliability of AI-EGGIM scoring. This is a prospective study designed to validate the AI-EGGIM system in a larger cohort. The study protocol was developed based on preliminary experience from a prior investigation (NCT05464108).
Trial Details
NCT Number NCT07257796
Lead Sponsor Qilu Hospital of Shandong University
Conditions Intestinal Metaplasia of Gastric Mucosa, Artificial Intelligence, Endoscopy
Enrollment 3,000 participants
Start Date 2025-11-01
Primary Completion 2027-05-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-02